Frazier Life Sciences SPAC raises $75M in Nasdaq IPO

Frazier Life Sciences Acquisition Corp. II, a special purpose acquisition company, closed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75,000,000 in total proceeds, according to a press release from the company.

The Class A ordinary shares are listed on the Nasdaq Capital Market under the ticker symbol NASDAQ: FLSC, with trading beginning Oct. 14, 2026. The SEC declared the registration statement effective on Oct. 13, 2026.

The company was formed to pursue a merger, share exchange, asset acquisition, or similar business combination. It intends to focus on the biotechnology sector, though it may consider opportunities across any industry or geography.

The company is sponsored by Frazier Life Sciences Holdings II, LLC, an affiliate of Frazier Life Sciences Management, L.P. Albert Cha, MD, PhD, serves as chief executive officer, Ben Palleiko as chairman of the board, and Kevin Li, M.D., as chief business officer.

Jefferies acted as the sole book-running manager for the offering.

You May Also Be Interested In

• Iambic Therapeutics prices IPO at $16 per share on Nasdaq
• First Tracks Biotherapeutics raises $200M in private placement
• Jasper Therapeutics completes IgAN cohort enrollment in Phase 2 study